CD8A and T-cell non-Hodgkin lymphoma: Activity of DCs may also be the only choice for immunotherapies of certain tumors, such as the T cell lymphomas in our model, because these cells are able to evade both CD8 T recognition, by downregulating MHC class I, and NK cell activities, by inducing their disappearance (5, 6).